Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim that INGREZZA/INGREZZA SPRINKLE is associated with increased risk of depression and suicidal ideation/behavior in Huntington’s disease is directly supported by the provided FDA label text (Boxed Warning and Section 5.1), with no contradictions identified.
Category Scores
Accurate Statements
INGREZZA/INGREZZA SPRINKLE use in Huntington’s disease is associated with risk of depression and suicidal ideation/behavior.
Boxed Warning: “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease.” and Section 5.1: “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk for suicidal ideation and behaviors in patients with Huntington’s disease.”
The label includes incidence data showing depression/depressed mood reported in 4.7% (INGREZZA) vs 1.6% (placebo), and suicidal ideation/behavior reports in clinical trials.
Section 5.1: “depression or depressed mood was reported in 4.7% of patients taking INGREZZA compared to 1.6% of patients who received placebo” and “Suicidal ideation (9 subjects; 7.2%) and suicide attempts (3 subjects; 2.4%) were reported in the longer open-label extension trial (N=125).”
Unsupported Statements
Contradictions
Important Omissions
No explicit mention of the label’s management/counseling instructions (e.g., closely monitor for new or worsening depression/suicidal ideation/behavior; consider discontinuing if not resolved).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated output concerns recognition of a boxed warning and is consistent with label-supported risk; it does not provide dosing, contraindications, or treatment instructions that would conflict with the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response states risk but omits key label-directed actions for monitoring/counseling described in the Boxed Warning/Section 5.1/Section 17.
Suggested Improvement
Include the label’s monitoring and patient/caregiver counseling instructions (e.g., closely monitor for new or worsening depression and suicidal ideation/behavior; instruct to report behaviors promptly; consider discontinuation if reactions do not resolve).